Healthy Returns

How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.

CNBC presents a one-day event that brings together top health care investors, CEOs and technologists to explore the innovations that will drive better outcomes, financially and clinically.

Every health care company seeks to scale the best technology and develop profitable ways to cover the massive cost of research and development, investors are looking for actionable intelligence on who’s breaking through, and patients are hungry for affordable and effective care. Healthy Returns is a convening of leaders who are improving patient outcomes, maximizing innovation, building great new companies and reinventing incumbents.

Led by CNBC’s anchors and reporters, Healthy Returns hones in on groundbreaking ideas that will transform the health care industry, cutting through the noise and weeding out the “sales pitch.”

Who should attend:

Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.

PAST EVENTS | 2018

SPEAKERS

Martine
Rothblatt

United Therapeutics

Martine Rothblatt is Chairman & CEO of United Therapeutics.

Martine Rothblatt

Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.

Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.

In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).

Alex
Gorsky

Johnson & Johnson

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee.

Alex Gorsky

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

Vasant
Narasimhan

Novartis

Vasant Narasimhan, M.D., is Chief Executive Officer of Novartis.

Vasant Narasimhan

Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.

Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.

Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.

Daphne
Koller

insitro

Daphne Koller is Founder and CEO of insitro.

Daphne Koller

Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.

Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.

Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.

Scott
Gottlieb

Fmr. U.S. Food and Drug Administration

Dr. Gottlieb is the former Commissioner of the U.S. Food and Drug Administration.

Scott Gottlieb

Dr. Scott Gottlieb is the former Commissioner of the U.S. Food and Drug Administration.

Dr. Gottlieb was sworn in as the 23rd commissioner of Food and Drugs on May 10, 2017. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s deputy commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner.

He also worked on implementation of the Medicare drug benefit as a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies.

In 2013 Scott Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on health care information technology.

Gottlieb was previously a resident fellow at the American Enterprise Institute, and a clinical assistant professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.

He completed a residency in internal medicine at the Mount Sinai Medical Center in New York City and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

Scarlet
Shore

Verily

Scarlet is head of product and platform lead for Project Baseline at Verily.

Scarlet Shore

Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.

Samarth
Kulkarni

CRISPR Therapeutics

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics.

Samarth Kulkarni

Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since December 2017.

He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, served a number of biotechnology companies on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as a member of the Casebia Board of Directors.

He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

Jennifer
Schneider

Livongo

Jennifer Schneider is President of Livongo.

Jennifer Schneider

Dr. Jennifer Schneider is the President of Livongo. In this role, she is responsible for product, data science, engineering, marketing, and clinical operations. Dr. Schneider previously served as the company’s Chief Medical Officer where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches.

Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health, most recently as Chief Medical Officer. She also has held leadership roles in the provider setting as a health outcomes researcher and Chief Resident at Stanford University, and has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross, a Doctor of Medicine degree from Johns Hopkins School of Medicine, and a Master of Science degree in Health Services Research from Stanford University. She completed her internal medicine residency at Stanford University Hospital.

Dr. Schneider is a frequent speaker about innovation in healthcare, where she shares her unique perspective as a practicing physician, health services researcher, senior executive and individual who has lived with Type 1 diabetes for more than 30 years. She has three children and is an avid runner and athlete, having completed her first IronMan in 2016.

SEE ALL

David
Cordani

Cigna

David Cordani is President and CEO of Cigna.

David Cordani

David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years. He is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements and partnering with physicians to focus on wellness, and improving clinical quality. With operations and capabilities in more than thirty countries, Cordani leads Cigna’s approximately 43,000 employees in improving the health, well-being and sense of security of more than 95 million customer relationships.

Cordani joined Cigna in 1991; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.

Prior to joining Cigna, Cordani was with Coopers & Lybrand. He actively works with the Achilles International Freedom Team of Wounded Veterans and ChildObesity180, where he is a charter board member. He also supports organizations including March of Dimes and The Juvenile Diabetes Research Foundation. In addition, he is founder of The David and Sherry Cordani Family Foundation, reflecting the Cordani family’s deep commitment to supporting community health and well-being. Cordani was named to the General Mills Board of Directors in 2014 and to the U.S.-India Business Council Board of Directors in 2015.

David Cordani is an accomplished triathlete, having competed in more than 125 triathlons. He earned a bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.

Peter
Lee

Microsoft Healthcare

Peter Lee is Corporate Vice President of Microsoft Healthcare.

Peter Lee

Dr. Peter Lee is Corporate Vice President, Microsoft Healthcare. He leads an organization that works on technologies for better and more efficient healthcare, with a special focus on artificial intelligence and cloud computing. Dr. Lee has extensive experience in managing the process of going from basic research to commercial impact. Past illustrative examples include the deep neural networks for simultaneous language translation in Skype, next-generation IoT technologies, and innovative silicon and post-silicon computer architectures for Microsoft’s cloud. He also has a history of advancing more “out of the box” technical efforts, such as experimental under-sea datacenters, augmented-reality experiences for HoloLens and VR devices, digital storage in DNA, and social chatbots such as XiaoIce and Tay. Previously, as an Office Director at DARPA, he led efforts that created operational capabilities in advanced machine learning, crowdsourcing, and big-data analytics, such as the DARPA Network Challenge and Nexus 7. He was formerly the Head of Carnegie Mellon University’s computer science department. As a thought leader, he has spoken and written widely on technology trends and policies, spanning the fields of computing technology, healthcare, and innovation ecosystem. He is a member of the Boards of Directors of the Allen Institute for Artificial Intelligence and the Kaiser Permanente School of Medicine. He served on President’s Commission on Enhancing National Cybersecurity. He has led studies for the National Academies on the impact of federal research investments on economic growth and testified before the US House Science and Technology Committee and the US Senate Commerce Committee.

Marc
Harrison

Intermountain Healthcare

Marc Harrison is the President and CEO of Intermountain Healthcare.

Marc Harrison

Dr. Harrison is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is leading Intermountain to embrace bold new approaches focused on improving health while continuing to make healthcare more effective, accessible, and affordable. As a result, Intermountain’s 37,000 employees—who are all called caregivers—continue to re-define value-based care and serve people in new ways.

Dr. Harrison is a national and international thought leader on healthcare transformation and innovation. In 2018, he ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders. He also tied for second on Modern Healthcare’s list of the 100 Most Influential People in Healthcare.

Two examples of innovations Intermountain is leading:
• Intermountain launched Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation.
• Intermountain is a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration between numerous community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital, such as chronic hunger, affordable housing, joblessness, personal safety, etc.

Dr. Harrison’s previous healthcare leadership experience has included service as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer at Cleveland Clinic.

He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a residency at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University.

Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.

John
Rogers

Northwestern University

John Rogers is a Professor of Biomedical Engineering and Medicine at Northwestern University.

John Rogers

John Rogers is a Professor of Materials Science and Engineering, Biomedical Engineering and Medicine at Northwestern University.

Rogers' research seeks to understand and exploit interesting characteristics of 'soft' materials, such as polymers, liquid crystals, and biological tissues as well as hybrid combinations of them with unusual classes of micro/nanomaterials, in the form of ribbons, wires, membranes, tubes or related. The aim is to control and induce novel electronic and photonic responses in these materials; and also develop new 'soft lithographic' and biomimetic approaches for patterning them and guiding their growth. This work combines fundamental studies with forward-looking engineering efforts in a way that promotes positive feedback between the two. Current research focuses on soft materials for conformal electronics, nanophotonic structures, microfluidic devices, and microelectromechanical systems, all lately with an emphasis on bio-inspired and bio-integrated technologies. These efforts are highly multidisciplinary, and combine expertise from nearly every traditional field of technical study.

Professor Rogers has invented over 80 patents and patent applications, more than 50 of which are licensed or in active use by large companies and startups that he has co-founded, including Active Impulse Systems, Semprius, MC10, CoolEdge, XCeleprint and Transient Electronics.

His education includes:
Ph.D. in Physical Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

S.M. in Physics, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

S.M. in Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

B.S. in Physics, University of Texas, Austin, Austin, TX

B.A. in Chemistry, University of Texas, Austin, Austin, TX

Andy
Slavitt

Town Hall Ventures

Andy is a General Partner at Town Hall Ventures.

Andy Slavitt

Andy is a general partner at Town Hall and brings decades of private and public sector leadership in health care, business and technology. Over his career, Andy has been a part of many of the most significant and successful initiatives in health care impacting millions of Americans and the shape of the health care system. Andy previously served as the Acting Administrator of the Center for Medicare and Medicaid Services (CMS) under President Obama. He spent a decade at Optum, an organization he helped lead from before its formal inception to the time where it exceeded $35 billion in revenue. In the 1990s, Andy was the founder and CEO of HealthAllies, a digital health company that served the un- and under-insured.

Andy is currently Board Chair of United States of Care, a national non-profit health advocacy organization he founded. Andy leads a number of national health care initiatives, including one on the future of health care, which he co-chairs at the Bipartisan Policy Center. Today he is a highly recognizable voice in health care, with a regular column in the USA Today and regular appearances on CNN, MSNBC and Fox. He is listed in the Politico 50 (right after Bob Mueller and right before Charles Kessler) and was recognized by Modern Healthcare as one of the 10 most influential people in health care.

Andy graduated from the College of Arts and Sciences and the Wharton School at the University of Pennsylvania and holds an MBA from the Harvard Business School. He was recently named a Distinguished Policy Fellow at the University of Pennsylvania. He lives in Minneapolis and on Twitter with his wife Lana and their two sons, Caleb, currently in college, and Zach, currently in high school, both of whom are fans of all things basketball and are active participants in conversations about world events with their parents.

SHOW LESS

SPEAKERS

MARTINE ROTHBLATT

United Therapeutics
Read Bio ⟶

MARTINE ROTHBLATT

Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.

Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.

In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
ALEX GORSKY

Johnson & Johnson
Read Bio ⟶

ALEX GORSKY

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
VASANT “VAS” NARASIMHAN

Novartis
Read Bio ⟶

VASANT “VAS” NARASIMHAN

Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.

Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.

Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
DAPHNE KOLLER

insitro
Read Bio ⟶

DAPHNE KOLLER

Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.

Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.

Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
SCOTT GOTTLIEB

Fmr. U.S. Food and Drug Administration
Read Bio ⟶

SCOTT GOTTLIEB

Dr. Scott Gottlieb is the former Commissioner of the U.S. Food and Drug Administration.

Dr. Gottlieb was sworn in as the 23rd commissioner of Food and Drugs on May 10, 2017. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s deputy commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner.

He also worked on implementation of the Medicare drug benefit as a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies.

In 2013 Scott Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on health care information technology.

Gottlieb was previously a resident fellow at the American Enterprise Institute, and a clinical assistant professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.

He completed a residency in internal medicine at the Mount Sinai Medical Center in New York City and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
SCARLET SHORE

Verily
Read Bio ⟶

SCARLET SHORE

Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.
SAMARTH KULKARNI

CRISPR Therapeutics
Read Bio ⟶

SAMARTH KULKARNI

Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since December 2017.

He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, served a number of biotechnology companies on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as a member of the Casebia Board of Directors.

He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.
JENNIFER SCHNEIDER

Livongo
Read Bio ⟶

JENNIFER SCHNEIDER

Dr. Jennifer Schneider is the President of Livongo. In this role, she is responsible for product, data science, engineering, marketing, and clinical operations. Dr. Schneider previously served as the company’s Chief Medical Officer where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches.

Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health, most recently as Chief Medical Officer. She also has held leadership roles in the provider setting as a health outcomes researcher and Chief Resident at Stanford University, and has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross, a Doctor of Medicine degree from Johns Hopkins School of Medicine, and a Master of Science degree in Health Services Research from Stanford University. She completed her internal medicine residency at Stanford University Hospital.

Dr. Schneider is a frequent speaker about innovation in healthcare, where she shares her unique perspective as a practicing physician, health services researcher, senior executive and individual who has lived with Type 1 diabetes for more than 30 years. She has three children and is an avid runner and athlete, having completed her first IronMan in 2016.
MARK BERTOLINI

Fmr. Aetna CEO
Read Bio ⟶

MARK BERTOLINI

Mark Bertolini is the Former CEO of Aetna.
DAVID CORDANI

Cigna
Read Bio ⟶

DAVID CORDANI

David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years. He is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements and partnering with physicians to focus on wellness, and improving clinical quality. With operations and capabilities in more than thirty countries, Cordani leads Cigna’s approximately 43,000 employees in improving the health, well-being and sense of security of more than 95 million customer relationships.

Cordani joined Cigna in 1991; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.

Prior to joining Cigna, Cordani was with Coopers & Lybrand. He actively works with the Achilles International Freedom Team of Wounded Veterans and ChildObesity180, where he is a charter board member. He also supports organizations including March of Dimes and The Juvenile Diabetes Research Foundation. In addition, he is founder of The David and Sherry Cordani Family Foundation, reflecting the Cordani family’s deep commitment to supporting community health and well-being. Cordani was named to the General Mills Board of Directors in 2014 and to the U.S.-India Business Council Board of Directors in 2015.

David Cordani is an accomplished triathlete, having competed in more than 125 triathlons. He earned a bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.
JEFF JONAS, M.D.

SAGE Therapeutics
Read Bio ⟶

JEFF JONAS, M.D.

Jeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.
CHRISTI SHAW

Eli Lilly and Company
Read Bio ⟶

CHRISTI SHAW

Christi Shaw is a senior vice president of Eli Lilly and Company and president of Lilly Bio-Medicines.

Before she rejoined Lilly in April 2017, she had most recently served as U.S. country head and president of Novartis Corporation.

Christi serves as a board member of the Biotechnology Industry Organization (BIO) and an advisor to the Healthcare Businesswomen’s Association. In 2018, Christi was honored with the Health Industry Visionary Award by the Society for Women’s Health Research. In May 2016, she was presented with Eye for Pharma’s prestigious Lifetime Achievement Award for her industry thought-leadership and dedication to the needs of patients. Also in 2016, PharmaVOICE named Shaw to its 100 Most Inspiring People list, and Diversity Journal included her on its roster of Women Worth Watching. Christi has spoken at leading industry conferences on the future of health care, driving innovation to support better patient outcomes and encouraging a diverse and inclusive culture. In addition, her perspectives have been featured in Working Mother and Life Science Leader magazines.

Christi worked at Lilly from 1989 to 2002 in sales and marketing roles, and she later held a series of increasingly responsible roles in the Janssen and Ethicon subsidiaries of Johnson & Johnson.

She earned a Bachelor of Business Administration from Iowa State University and an MBA from the University of Wisconsin.

In 2017, Shaw founded the More Moments More Memories Foundation to assist people with cancer and their caregiver.
JORGE CONDE

Andreessen Horowitz
Read Bio ⟶

JORGE CONDE

Jorge Conde is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and health.
Prior to joining a16z, Jorge served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Jorge also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University.
Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a 2015 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He serves on the board of the Museum of Science, Boston.
PETER LEE

Microsoft Healthcare
Read Bio ⟶

PETER LEE

Dr. Peter Lee is Corporate Vice President, Microsoft Healthcare. He leads an organization that works on technologies for better and more efficient healthcare, with a special focus on artificial intelligence and cloud computing. Dr. Lee has extensive experience in managing the process of going from basic research to commercial impact. Past illustrative examples include the deep neural networks for simultaneous language translation in Skype, next-generation IoT technologies, and innovative silicon and post-silicon computer architectures for Microsoft’s cloud. He also has a history of advancing more “out of the box” technical efforts, such as experimental under-sea datacenters, augmented-reality experiences for HoloLens and VR devices, digital storage in DNA, and social chatbots such as XiaoIce and Tay. Previously, as an Office Director at DARPA, he led efforts that created operational capabilities in advanced machine learning, crowdsourcing, and big-data analytics, such as the DARPA Network Challenge and Nexus 7. He was formerly the Head of Carnegie Mellon University’s computer science department. As a thought leader, he has spoken and written widely on technology trends and policies, spanning the fields of computing technology, healthcare, and innovation ecosystem. He is a member of the Boards of Directors of the Allen Institute for Artificial Intelligence and the Kaiser Permanente School of Medicine. He served on President’s Commission on Enhancing National Cybersecurity. He has led studies for the National Academies on the impact of federal research investments on economic growth and testified before the US House Science and Technology Committee and the US Senate Commerce Committee.
ALETHIA YOUNG

Cantor Fitzgerald
Read Bio ⟶

ALETHIA YOUNG

Alethia Young is the Large Cap Biotech Analyst and Head of Healthcare Research at Cantor Fitzgerald.
BOB SHEEHY

Fmr. Unitedhealthcare CEO
Read Bio ⟶

BOB SHEEHY

Bob Sheehy is co-founder and CEO of Bright Health, and former CEO of UnitedHealthcare. He was also Executive Partner at Flare Capital.
MARC HARRISON

Intermountain Healthcare
Read Bio ⟶

MARC HARRISON

Dr. Harrison is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is leading Intermountain to embrace bold new approaches focused on improving health while continuing to make healthcare more effective, accessible, and affordable. As a result, Intermountain’s 37,000 employees—who are all called caregivers—continue to re-define value-based care and serve people in new ways.

Dr. Harrison is a national and international thought leader on healthcare transformation and innovation. In 2018, he ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders. He also tied for second on Modern Healthcare’s list of the 100 Most Influential People in Healthcare.

Two examples of innovations Intermountain is leading:
• Intermountain launched Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation.
• Intermountain is a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration between numerous community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital, such as chronic hunger, affordable housing, joblessness, personal safety, etc.

Dr. Harrison’s previous healthcare leadership experience has included service as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer at Cleveland Clinic.

He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a residency at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University.

Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.
ASHISH JHA

Harvard Global Health Institute
Read Bio ⟶

ASHISH JHA

Ashish Jha, MD, MPH, is the Dean for Global Strategy and K.T. Li Professor of Global Health at the Harvard T.H. Chan School of Public Health and the Director of the Harvard Global Health Institute. He is also a practicing General Internist at the VA Boston Healthcare System and Professor of Medicine at Harvard Medical School. Dr. Jha received his MD from Harvard Medical School and then trained in Internal Medicine at the University of California in San Francisco. He completed his General Medicine fellowship at Brigham & Women’s Hospital at Harvard Medical School and received his MPH from the Harvard T.H. Chan School of Public Health. His research endeavors focus on improving the quality and costs of health care systems with a specialized focus on the impact of policies. Dr. Jha has published over two hundred empirical papers and writes regularly about ways to improve health care systems, both in the U.S. and globally. Dr. Jha was elected as a member of the National Academy of Medicine in 2013.
PETER ORSZAG

Lazard
Read Bio ⟶

PETER ORSZAG

Before joining Lazard, Peter served as Vice Chairman of Corporate and Investment Banking and Chairman of the Financial Strategy and Solutions Group at Citigroup, Inc. He previously served as the Director of the Office of Management and Budget in the Obama Administration and before that as Director of the Congressional Budget Office. Earlier in his career, Peter was the Joseph A. Pechman Senior Fellow and Deputy Director of Economic Studies at the Brookings Institution. During the Clinton Administration, he was a Special Assistant to the President for Economic Policy and before that a staff economist and then Senior Advisor and Senior Economist at the President's Council of Economic Advisers. Orszag has also founded and subsequently sold an economics consulting firm.
Peter graduated summa cum laude in economics from Princeton University and obtained a Ph.D. in economics from the London School of Economics, which he attended as a Marshall Scholar. He has coauthored or coedited a number of books and serves on the Board of Directors of the Peterson Institute for International Economics, Mt. Sinai Medical Center, New Visions for Public Schools, and the Russell Sage Foundation. He is also a member of the National Academy of Medicine.
JOHN ROGERS

Northwestern University
Read Bio ⟶

JOHN ROGERS

John Rogers is a Professor of Materials Science and Engineering, Biomedical Engineering and Medicine at Northwestern University.

Rogers' research seeks to understand and exploit interesting characteristics of 'soft' materials, such as polymers, liquid crystals, and biological tissues as well as hybrid combinations of them with unusual classes of micro/nanomaterials, in the form of ribbons, wires, membranes, tubes or related. The aim is to control and induce novel electronic and photonic responses in these materials; and also develop new 'soft lithographic' and biomimetic approaches for patterning them and guiding their growth. This work combines fundamental studies with forward-looking engineering efforts in a way that promotes positive feedback between the two. Current research focuses on soft materials for conformal electronics, nanophotonic structures, microfluidic devices, and microelectromechanical systems, all lately with an emphasis on bio-inspired and bio-integrated technologies. These efforts are highly multidisciplinary, and combine expertise from nearly every traditional field of technical study.

Professor Rogers has invented over 80 patents and patent applications, more than 50 of which are licensed or in active use by large companies and startups that he has co-founded, including Active Impulse Systems, Semprius, MC10, CoolEdge, XCeleprint and Transient Electronics.

His education includes:
Ph.D. in Physical Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

S.M. in Physics, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

S.M. in Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts

B.S. in Physics, University of Texas, Austin, Austin, TX

B.A. in Chemistry, University of Texas, Austin, Austin, TX
ANDY SLAVITT

Town Hall Ventures
Read Bio ⟶

ANDY SLAVITT

Andy is a general partner at Town Hall and brings decades of private and public sector leadership in health care, business and technology. Over his career, Andy has been a part of many of the most significant and successful initiatives in health care impacting millions of Americans and the shape of the health care system. Andy previously served as the Acting Administrator of the Center for Medicare and Medicaid Services (CMS) under President Obama. He spent a decade at Optum, an organization he helped lead from before its formal inception to the time where it exceeded $35 billion in revenue. In the 1990s, Andy was the founder and CEO of HealthAllies, a digital health company that served the un- and under-insured.

Andy is currently Board Chair of United States of Care, a national non-profit health advocacy organization he founded. Andy leads a number of national health care initiatives, including one on the future of health care, which he co-chairs at the Bipartisan Policy Center. Today he is a highly recognizable voice in health care, with a regular column in the USA Today and regular appearances on CNN, MSNBC and Fox. He is listed in the Politico 50 (right after Bob Mueller and right before Charles Kessler) and was recognized by Modern Healthcare as one of the 10 most influential people in health care.

Andy graduated from the College of Arts and Sciences and the Wharton School at the University of Pennsylvania and holds an MBA from the Harvard Business School. He was recently named a Distinguished Policy Fellow at the University of Pennsylvania. He lives in Minneapolis and on Twitter with his wife Lana and their two sons, Caleb, currently in college, and Zach, currently in high school, both of whom are fans of all things basketball and are active participants in conversations about world events with their parents.
DR. FARZAD MOSTASHARI

Aledade
Read Bio ⟶

DR. FARZAD MOSTASHARI

Co-Founder and CEO Farzad Mostashari, MD has spent his career at the forefront of health care policy and health information technology. Dr. Mostashari is the former National Coordinator for Health IT at the Department of Health and Human Services, and served as a distinguished expert at the Brookings Institute’s Engelberg Center for HealthCare Reform. Prior to his work at the Office of the National Coordinator, he founded the NYC Primary Care Information Project, which equipped 1,500 physicians in underserved communities with electronic health records. He has spoken and written extensively on issues affecting health IT, ACOs, and health care policy and delivery. He has been published in the New York Times, the Journal of American Medical Association, and Health Affairs, among others. Dr. Mostashari received his MD from Yale University School of Medicine and his Masters in Population Health from Harvard T.H. Chan School of Public Health.
TIM WENTWORTH

Express Scripts
Read Bio ⟶

TIM WENTWORTH

Tim Wentworth is Chief Executive Officer and President of Express Scripts. He is responsible for all aspects of the company’s strategic direction and core business, including sales and account management, information technology, operations, research and new solutions, and supply chain management. Tim was named President in 2014 and Chief Executive Officer in 2016. Tim joined Express Scripts when the company merged with Medco in April 2012. At Medco, he led the employer and key accounts organizations for nearly 14 years. He also served as President and CEO of Accredo, the company's specialty pharmacy. He earned a bachelor's degree in industrial and labor relations from Cornell University and an associate's degree in business from Monroe Community College.
ALI SATVAT

KKR
Read Bio ⟶

ALI SATVAT

Ali J. Satvat (Menlo Park) joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Coherus BioSciences, Eidos Therapeutics, Falcon Vision, Headlands Research, Impel NeuroPharma, Slayback Pharma and Trilogy MedWaste and has also been involved in KKR’s investments in Ajax Health, GenesisCare, Gland Pharma, Panasonic Healthcare, PRA Health Sciences and Spirox. Prior to joining KKR, Mr. Satvat was a principal with Apax Partners, where he invested in health care and was actively involved with many of the firm’s successful private equity and growth equity investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat is a member of the board of directors of the Healthcare Private Equity Association.
JEFF BORGHOFF

Alzheimer's Patient
Read Bio ⟶

JEFF BORGHOFF

Jeff Borghoff was diagnosed with younger onset / early-stage Alzheimer's disease in 2016 at the age of 51. A former IT professional, Jeff is now leading a charge against Alzheimer's disease. Since his diagnoses, he has served as a member of the Alzheimer's Association's national Early Stage Advisor Group. Currently he is serving as an Alzheimer's Impact Movement congressional team member, a member of the Alzheimer’s Association of Greater NJ Chapter's board of directors, and a sub-committee member to the National Institute on Aging (NIA). Jeff and his family are featured in the forthcoming public television documentary film 'SPENT - The Hidden Cost of Dementia'. Jeff was also a participant in Biogen’s failed clinical trial for Alzheimer’s.

AGENDA

8:00am - 9:00am

Registration and Networking Breakfast

9:00am - 12:30pm

Morning Sessions

Interview with Former FDA Commissioner Scott Gottlieb
A conversation with one of the most influential FDA commissioners ever, about the industry he regulated and the future of the pharmaceutical industry.
Interviewer: Meg Tirrell, Biotech and pharma reporter, CNBC

The Big-Pharma View
The CEO of Novartis, the Swiss-based pharma behemoth, talks innovation, new pricing models and new product pipelines, all at scale.
Dr. Vasant “Vas” Narasimhan, CEO, Novartis
Interviewer: Jim Cramer, Host of “Mad Money w/ Jim Cramer” & Co-Anchor “Squawk on the Street,” CNBC

DIY Generics
Faced with ever-rising prices for oft-used generic drugs, one provider decided to make its own. We check in with one of its founders on the progress of Civica Rx.
Dr. Marc Harrison, President and CEO, Intermountain Health

The New Model
Their hope in combining their companies in a $54 billion deal is to contain costs for employers and to leverage data to create more integrated care for consumers. We ask, how is it going so far?
David Cordani, President and CEO, Cigna
Tim Wentworth, President, Express Scripts and Cigna Services; Fmr CEO, Express Scripts
Interviewer: To be announced

Moonshots: Martine Rothblatt on the Future of Health Care
There are few, if any, more innovative, more daring and more iconic health-care executives. We’ll hear about the processes that drive groundbreaking invention, and her dream of permanently alleviating the shortage of transplantable organs.
Martine Rothblatt, Founder and CEO, United Therapeutics; Founder and Fmr CEO, Sirius Satellite Radio
Presentation followed by Q & A with Melissa Lee, Host, “Fast Money,” and co-anchor, “Power Lunch,” CNBC

Live Demonstration: Sweating, the Details
How, and what, you sweat can tell you a lot about what’s going on in your body.
Dr. John Rogers, Professor, Biomedical Engineering and Neurological Surgery, Northwestern University Feinberg School of Medicine
Interviewer: Christina Farr, Technology and Health Reporter, CNBC.com

12:30pm - 1:45pm

Lunch

1:45pm - 5:00pm

Afternoon Sessions

What’s Next: Deals and IPOs
What companies are candidates for acquisition? Which unicorns will go public? Where will private money flow? Let’s find out.
Peter Orszag, Head of North American M&A, Vice Chairman of Investment Banking, Global Co-Head of Health Care, Lazard Frères & Co.
Jorge Conde, General Partner, Andreessen Horowitz
Ali Satvat, Member, Private Equity, KKR
Moderator: David Faber, Co-anchor, “Squawk on the Street,” CNBC

Genetics, CRISPR and Medical Ethics
It’s perhaps the most promising medical technology in a generation, but how can we ensure its responsible use?
Paul Dabrowski, CEO, Synthego
Dr. Samarth Kulkarni, CEO, CRISPR Therapeutics
Moderator: Meg Tirrell, Biotech and pharma reporter, CNBC

Transformation: Data, A.I. and Health Care
A rapid-fire discussion of the ways drug development, diagnostics and delivery are being reinvented with the use of big data analysis and artificial intelligence.
Daphne Koller, Founder and CEO, insitro
Dr. Jennifer Schneider, President, Livongo
Peter Lee, AI Research, Microsoft Health
Dr. Farzad Mostashari, Co-founder and CEO, Aledade
Moderator: Christina Farr, Technology and Health Reporter, CNBC.com

Defining the Future of US Health Care
Groundbreaking technology, backbreaking costs, policy battles, incredible cures. A panel of leading health-care influencers discuss what they see coming next.
Dr. Ashish Jha, Global Health Director, Harvard University
Bob Sheehy, Co-founder and CEO, Bright Health; Fmr CEO, UnitedHealthcare
Andy Slavitt, General Partner, Town Hall Ventures; Fmr Commissioner, CMS
Moderator: To be announced

The View from New Brunswick
What the future health-care landscape looks like from atop one of the world’s biggest and most admired health-care companies.
Alex Gorsky, Chairman and CEO, Johnson & Johnson
Interviewer: Meg Tirrell, Biotech and pharma reporter, CNBC

5:00pm - 6:00pm

Cocktail Reception

IMAGE GALLERY

EVENT PHOTO GALLERY

EVENT
VIDEOS

/ 2

The Best of Healthy Returns

How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open Video
Healthy Returns

Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open Video

EVENT VIDEOS

The Best of Healthy Returns

How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open Video
Healthy Returns

Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open Video

Venue

New York Hilton Midtown, 1335 6th Ave, New York, NY 10019

DIRECTIONS

Accommodations

A limited number of guestrooms have been reserved for Healthy Returns attendees at the reduced room rate of $309/night (+taxes and fees). A deposit of first night’s room and tax will be charged at the time of booking. Deposits are refundable up to 72 hours prior to arrival.

To book please contact Hilton Reservations at 212-586-7000 and request the Healthy Returns rate or book online here.

Contact

SPONSORSHIP OPPORTUNITIES

SPEAKER + EDITORIAL SUBMISSIONS

INTERNATIONAL INQUIRIES

PRESS + MEDIA INQUIRES

GENERAL INQUIRIES

SPEAKERS

MartineRothblatt

Martine Rothblatt

AlexGorsky

Alex Gorsky

Vasant Narasimhan

Vasant Narasimhan

Daphne Koller

Daphne Koller

Scott Gottlieb

Scott Gottlieb

ScarletShore

Scarlet Shore

SamarthKulkarni

Samarth Kulkarni

Jennifer Schneider

Jennifer Schneider

SEE ALL

MarkBertolini

Mark Bertolini

DavidCordani

David Cordani

JeffJonas

Jeff Jonas

ChristiShaw

Christi Shaw

JorgeConde

Jorge Conde

PeterLee

Peter Lee

Alethia Young

Alethia Young

Bob Sheehy

Bob Sheehy

MarcHarrison

Marc Harrison

Ashish Jha

Ashish Jha

PeterOrszag

Peter Orszag

John Rogers

John Rogers

Andy Slavitt

Andy Slavitt

Farzad Mostashari

Farzad Mostashari

TimWentworth

Tim Wentworth

Ali Satvat

Ali Satvat

Jeff Borghoff

Jeff Borghoff

SHOW LESS

SPEAKERS

MARTINE ROTHBLATT

MARTINE ROTHBLATT

ALEX GORSKY

ALEX GORSKY

VASANT “VAS” NARASIMHAN

VASANT “VAS” NARASIMHAN

DAPHNE KOLLER

DAPHNE KOLLER

SCOTT GOTTLIEB

SCOTT GOTTLIEB

SCARLET SHORE

SCARLET SHORE

SAMARTH KULKARNI

SAMARTH KULKARNI

JENNIFER SCHNEIDER

JENNIFER SCHNEIDER

MARK BERTOLINI

MARK BERTOLINI

DAVID CORDANI

DAVID CORDANI

JEFF JONAS, M.D.

JEFF JONAS, M.D.

CHRISTI SHAW

CHRISTI SHAW

JORGE CONDE

JORGE CONDE

Martine
Rothblatt

Alex
Gorsky

Vasant
Narasimhan

Daphne
Koller

Scott
Gottlieb

Scarlet
Shore

Samarth
Kulkarni

Jennifer
Schneider

Mark
Bertolini

David
Cordani

Jeff
Jonas

Christi
Shaw

Jorge
Conde

Peter
Lee

Alethia
Young

Bob
Sheehy

Marc
Harrison

Ashish
Jha

Peter
Orszag

John
Rogers

Andy
Slavitt

Farzad
Mostashari

Tim
Wentworth

Ali
Satvat

Jeff
Borghoff

EVENT
VIDEOS